Ionis Pharmaceuticals (IONS) Retained Earnings (2009 - 2026)

Ionis Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at -$2.7 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 13.64% year-over-year to -$2.7 billion; the TTM figure through Mar 2026 stood at -$2.7 billion (down 13.64% YoY), while the FY2025 annual figure was -$2.6 billion, down 8439.79% from the prior year.
• Retained Earnings was -$2.7 billion for Q1 2026 at Ionis Pharmaceuticals, down from -$2.6 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$24.2 million in Q3 2024 to a low of -$2.7 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$1.5 billion across 5 years, with a median of -$1.6 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings soared 98.65% in 2024, then slumped 9835.88% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$1.4 billion in 2022, then slipped by 25.62% to -$1.8 billion in 2023, then jumped by 98.28% to -$30.8 million in 2024, then plunged by 8439.79% to -$2.6 billion in 2025, then fell by 3.52% to -$2.7 billion in 2026.
• The last three Retained Earnings figures came in at -$2.7 billion (Q1 2026), -$2.6 billion (Q4 2025), and -$2.4 billion (Q3 2025), per Business Quant data.